Immunome Inc. (IMNM) - Form 8-K Summary
Business Context and Reporting Period
Immunome Inc. filed this Current Report on Form 8-K on August 11, 2026. The filing announces the financial results for the second quarter ended June 30, 2026, and provides a business update. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol IMNM.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not included in the provided text.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative financial data and operational updates.
Guidance, Outlook, and Risks
The Company provided a business update in the referenced press release. The filing explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933. Consequently, this information shall not be deemed incorporated by reference into other SEC filings unless expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 11, 2026) for specific Q2 2026 financial figures.
- Verify the Company's cash position and runway given the lack of specific liquidity data in the 8-K text.
- Confirm any updates to clinical trial progress or regulatory milestones mentioned in the business update.
- Note the legal disclaimer regarding the "furnished" status of the financial results, which limits liability and incorporation by reference.